ResearchEffect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled Trial
ResearchScoping review of echocardiographic parameters associated with diagnosis and prognosis after resuscitated sudden cardiac arrest
ResearchEffect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial
ResearchTotal events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial
ResearchDiagnostic yield, safety, and outcomes of Head-to-pelvis sudden death CT imaging in post arrest care: The CT FIRST cohort study
ResearchRisk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes
ResearchProtein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study
ResearchDulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial
ResearchReply to the letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial'
ResearchLong-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
ResearchCardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease
ResearchEarly head-to-pelvis computed tomography in out-of-hospital circulatory arrest without obvious etiology
ResearchHealth-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries
ResearchCardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease